Molecule Information

General Information of the Molecule (ID: Mol01793)

• Name: Long non-protein coding RNA (BDLNR) ,Homo sapiens
• Molecule Type: LncRNA

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Baicalein

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Cervical cancer [1]

• Sensitive Disease: Cervical cancer [ICD-11: 2C77.0]
• Sensitive Drug: Baicalein
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: Hela cells; Cervix uteri; Homo sapiens (Human); CVCL_0030
• In Vitro Model: Siha cells; Cervix uteri; Homo sapiens (Human); CVCL_0032
• In Vitro Model: Caski cells; Uterus; Homo sapiens (Human); CVCL_1100
• In Vitro Model: ME-180 cells; Uterus; Homo sapiens (Human); CVCL_1401
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Glo cell viability assays
• Mechanism Description: Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3 k/Akt pathway. BDLNR physically bound to YBX1, recruited YBX1 to PIk3CA promoter, activated PIk3CA expression and PI3 k/Akt pathway.

References

• Ref 1: Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway. Int J Biochem Cell Biol. 2018 Jan;94:107-118. doi: 10.1016/j.biocel.2017.11.009. Epub 2017 Nov 23.